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A B S T R A C T
Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and
the third most common cause of cancer death worldwide. The incidence of HCC in the United
States is rising steadily because of the prevalence of hepatitis C viral infection and other causes
of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which compli-
cates patient management and the search for safe and effective therapies. The Clinical Trials
Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute’s Gastrointestinal
Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research
priorities. The CTPM structured its review according to current evidence-based treatment
modalities in HCC and prioritized the recommendations on the basis of the patient populations
representing the greatest unmet medical need.
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INTRODUCTION
The most common primary malignancy of the liver
in adults is hepatocellular carcinoma (HCC, or hep-
atoma). It is currently the fifth most common solid
tumor worldwide and the third leading cause of
cancer-related death.1,2 Based on data for the period
1975 to 2006, liver cancer incidence and death rates
are steadily rising in the United States and demon-
strate the highest average annual percent increase
of the top 15 cancers by incidence.3 Despite ad-
vances in many aspects of HCC treatment, includ-
ing liver transplantation, surgical resection, and
locoregional therapies,  70% of HCC patients
present with advanced disease and will not benefit
from these treatment modalities. At present, only
one chemotherapeutic agent is approved for ad-
vanced HCC patients. This large majority of HCC
patients represents a significant unmet medical need
for more effective systemic therapy options. Most
HCC patients have underlying cirrhosis and hepatic
dysfunction—one patient with two diseases—that
can significantly complicate patient management
and clinical trial eligibility.
To more fully understand the complexities of
HCC and to identify the key unanswered research
questions and clinical trial priorities for HCC, the
Cancer Therapeutics Evaluation Program (CTEP)
and the Gastrointestinal Cancer Steering Commit-
tee (GISC) of the United States National Cancer
Institute (NCI) held a multidisciplinary workshop
inDecember2008titled“HepatocellularCarcinoma—
State of the Clinical Science.” The goals and objec-
tives of this Clinical Trials Planning Meeting
(CTPM) were to identify the critical clinical ques-
tions and unmet needs in hepatocellular carcinoma;
develop strategies for the design, initiation, and con-
duct of future clinical trials in HCC and provide
rationale for the recommendations; reach consensus
on the most important clinical trials to be developed,
especially those conducted by cooperative groups,
both near-term (6-12 months) and longer term
(18-36 months); and facilitate innovation and col-
laboration among clinicians and scientists.
This report describes the relevant background
on HCC, the approach and methods used in con-
ducting the CTPM, the outcome of the meeting, and
recommendations made to the NCI.
METHODOLOGY AND GOALS OF THE CTPM
To integrate research priorities and promote collab-
oration across the US Cancer Cooperative Groups,
the NCI has developed scientific steering commit-
tees, including disease-specific steering commit-
tees, that include broad leadership representation
from each of the 10 US Cancer Cooperative
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Groups and NCI Canada. The goal of each disease-specific steering
committee is to coordinate the identification, prioritization, and
development of clinical concepts in each specific tumor type. The
GISC, its Hepatobiliary Task Force, and NCI senior leadership
participated in planning and conducting the HCC CTPM. An
Executive Planning Committee was created that (1) identified rec-
ognized experts in all aspects of HCC management, with a goal of
ensuring multidisciplinary and international representation; (2)
created an interactive agenda that included high-level succinct
summary presentations of the current status of each treatment
category, question and answer sessions, panel discussions, small
group workshops, and report-back and review sessions; and (3)
tasked speakers, panelists, and participants to identify the key
knowledge gaps in HCC and define priorities for clinical trials and
their associated challenges.
HCC is an exceedingly heterogeneous malignancy because of its
multiple etiologies and the comorbidities resulting from underlying
cirrhosis that manifest as a broad range of liver dysfunction.4,5 Several
tumor staging and prognostic systems have been developed for HCC,
yet none is universally accepted or consistently used in clinical trials.
Many academic cancer centers in the United States and globally have
adopted therapeutic decision-making approaches to HCC similar to
that shown in Figure 1.6,7 Therapeutic advances in HCC have largely
evolved according to these treatment categories, specifically liver
transplantation, resection, local ablation, intrahepatic regional ther-
apy, and systemic therapy; thus, they were used as the framework for
the HCC CTPM agenda.
OVERVIEW OF HCC EPIDEMIOLOGY
The primary risk factor for HCC is liver injury from diverse causes that
leads to hepatic cirrhosis in most but not all patients. An estimated
78% of HCC cases and 57% of cases of liver cirrhosis are caused by
chronic infection with hepatitis B virus (HBV) or hepatitis C virus
(HCV).8-10 Chronic HBV infection, which occurs when the acute
infection is not cleared by the immune system, is associated with a 15%
to 25% risk of premature death from liver cancer or end-stage liver
disease.11,12 Approximately 600,000 people die worldwide from HBV-
related liver disease or HCC each year.4,13 In North America and in
other western countries, HCV is the leading etiology for HCC. In the
United States, an estimated 2.7 to 3.9 million people are chronically
infected with HCV, 20% will develop cirrhosis over 20 to 30 years, and
as many as 5% will die of HCC. Largely as a consequence of HCV-
related cirrhosis, the incidence of HCC tripled in the United States
from 1975 through 2005.14,15
Recently, the combination of insulin resistance, hypertension,
dyslipidemia, and obesity, termed “metabolic syndrome,” has been
recognized as a cause of nonalcoholic fatty liver disease, cirrhosis, and
HCC.16 There is increasing evidence that the risk of developing HCC
in nonalcoholic fatty liver disease–related chronic liver disease is be-
tween 18% and 27%, which is greater than the risk of developing HCC
in HCV-related cirrhosis.17-19 Hemochromatosis is also a significant
risk factor for HCC, with an increased relative risk 200 times that of the
normal population.20
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RFA PEI/cryoablation, TACE, sterotactic 
radiotherapy, or radiotherapeutic microspheres 
may be alternatives depending on tumor 
characteristics, location, and local expertise  
Child-Pugh A/B*
Fig 1. General treatment algorithm for hepatocellular carcinoma. *Suitability of patients with Child-Pugh class B cirrhosis for surgical resection is highly controversial. PVE,
portal vein embolization; mets, metastasis; TACE, transcatheter arterial chemoembolization; ETOH, ethanol; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection.
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IMAGING AND ASSESSMENT OF TREATMENT RESPONSE
HCC tumors are highly vascular tumors that are preferentially sup-
plied by hepatic artery branches rather than the portal venous system,
which normally provides 70% of the blood flow to liver parenchy-
ma.21,22 Abdominal ultrasound is a simple, noninvasive technique
that is commonly used in conjunction with serum -fetoprotein
(AFP) measurements in primary screening of patients at high risk of
developing HCC. HCC tumors are optimally imaged using four-
phase techniques, and these tumors typically demonstrate contrast
enhancement in the arterial phase and washout of contrast media in
the portal venous phase.23-25 In the United States, computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) are the current
preferred modalities for imaging HCC.26
The most widely used but least well understood imaging bi-
omarker for assessing treatment response is change in unidimen-
sional tumor size. The Response Evaluation Criteria in Solid Tumors
(RECIST) system is commonly used for evaluation of response to
therapies.
27, 28
There are numerous limitations of unidimensional mea-
surements, particularly when evaluating the effect of biologic targeted
agents in solid tumors: single-dimension measurements are a poor
surrogate for tumor volume, linear tumor size measurements are
challenging to reliably reproduce, and size alone does not capture the
biologic effect of treatment.29-31 Furthermore, the RECIST system is a
particularly limited metric for evaluating response, progression, and
the presence of new lesions in HCC because of (1) noncompliant
cirrhotic liver that may not remodel around dead tumor; (2) the
diffuse, infiltrative nature of HCC in many cirrhotic livers; (3) the
alteration of tumor vascularity but not tumor size commonly ob-
served with biologic agents; and (4) arterial phase enhancement of
premalignant dysplastic nodules commonly yielding radiographic
false-positive progressive disease.
STAGING AND PROGNOSTIC SYSTEMS
Cancer staging is an important prognostic tool that provides a classi-
fication system to help guide patient management, provides a com-
mon language to compare results of various clinical trials, and is
essential to the rational design of clinical trials. Currently, no single
staging system has been widely validated across the spectrum of HCC
patients, and none of the numerous systems has been adopted
globally.32-34 It is extremely challenging to develop a single, reproduc-
ible staging system in HCC because of significant patient heterogene-
ity related to multiple underlying etiologies and the presence of
compensated or decompensated cirrhosis.35 Based on common fea-
tures shared by several staging systems, the key factors that have an
impact on HCC prognosis and treatment option selection are solitary
versus multifocal tumors, presence of macrovascular invasion, extra-
hepatic disease, high serum AFP levels, patient performance status,
and degree of hepatic impairment. The principal HCC prognostic
systems in current use are summarized in Table 1.
CURRENT TREATMENT APPROACHES
Progress has been made in several aspects of HCC management,
including improved treatment of HCV,51-53 decreased incidence of
HBV infection as a result of widespread successful vaccination
efforts,54-56 enhanced screening and early HCC detection in high-risk
patients in some countries,13 and the approval in 2007 of the oral
anticancer agent sorafenib for treatment of advanced HCC.57,58 A
variety of treatment options are available for HCC patients; however,
at present, the only curative option is liver transplantation, which
benefits a small minority of HCC patients. Given the projected in-
crease in incidence of HCC due to HCV and obesity-related
cirrhosis,59-61 there is a looming need for accelerated clinical and
translational research in this disease.
The standard surgical management for early-stage HCC consists
of resection or liver transplantation. However, only 10% to 30% of
patients initially presenting with HCC will be eligible for surgery.62 In
general, the treatment of HCC is dependent not only on the extent of
tumor but also on the level of underlying hepatic dysfunction. Patients
with cirrhosis may be candidates for limited surgical resection, liver
transplantation, or locoregional ablative treatment, depending on the
severity of the cirrhosis. In patients with no evidence of cirrhosis,
hepatic resection has been the mainstay of surgical treatment. In
patients with moderate to severe cirrhosis (Child-Pugh class B or C),
transplantation is potentially optimal therapy for small-size, otherwise
resectable HCC, because it eliminates the underlying cirrhosis that
puts the liver at risk for subsequent new primary tumors.63-65 The ideal
treatment strategy, but also more controversial for small HCC in
patients with mild cirrhosis may include resection or transplanta-
tion.66,67 However, because of limited donor organ availability and
also for cultural and economic reasons, surgical resection is the main-
stay of therapy worldwide for patients with liver-confined HCC.
The selection of patients for surgical resection is based on several
criteria, including the absence of extrahepatic disease, the degree of
hepatic dysfunction, and technical considerations such as the ade-
quacy of the future liver remnant and tumor involvement of major
vascular structures such as the portal vein or vena cava. Patients with
normal liver parenchyma are usually eligible for extensive resection,
whereas patients with compensated cirrhosis may be candidates for
minor or major partial hepatectomy only in selected cases. Surgery in
patients with underlying cirrhosis can be associated with substantial
morbidity and mortality.68,69 Although perioperative mortality can be
as high as 30% to 50% in patients who are Child-Pugh class B or C,
patients who are Child-Pugh class A have a surgical mortality of only
5% to 10%.70,71 The model for end-stage liver disease (MELD) in-
cludes serum bilirubin, creatinine, and international normalized ratio
and has been shown to be a simple yet accurate method for predicting
postoperative liver failure and mortality. Patients with MELD score
 9 had a mortality rate of zero in two recent large institutional series
of patients undergoing resection of HCC.69,72 In most series, surgical
resection of early HCC reported 5-year survival rates of 45% to 50%
compared with 65% to 70% for transplantation.64 However, direct
comparison of resection to transplantation survival data is difficult
outside of a study designed to do that. The favorable results with
transplantation likely reflect more stringent selection of patients.73,74
Initial results for orthotopic liver transplantation (OLT) for all-
stage HCCs were associated with high early recurrence (18%) and
lower 5-year survival rates (40%) compared with other indications for
OLT.75 As a result of these discouraging experiences, in the early 1990s,
HCC was considered a contraindication to OLT in many transplanta-
tion centers. Subsequently, it was observed on examination of liver
explants that incidental small HCC not detected by preoperative
Thomas et al
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imaging had no adverse impact on the post-transplantation out-
come. Patients with HCC meeting these criteria (a single tumor  5
cm in diameter, or 2-3 tumors each  3 cm) had similar post-
transplantation survival compared with patients without HCC, with
4-year actuarial and recurrence-free survival rates of 75% and 83%,
respectively.76,77 These results have been confirmed by multiple cen-
ters and have led to the acceptance of liver transplantation for HCC in
cirrhotic patients who meet these criteria. HCC patients who undergo
OLT within United Network for Organ Sharing (UNOS) criteria have
median 5-year survivals of 65% to 80%. While there is interest in
expanding the criteria for liver transplantation for patients with HCC
to include patients with larger and more numerous tumors (the Uni-
versity of California at San Francisco [UCSF] criteria),78-81 these cri-
teria have not been universally accepted or adopted.
For selected patients with HCC confined to the liver whose dis-
ease is not amenable to resection or transplantation, locoregional
therapies can be considered. These include percutaneous ethanol in-
jection, cryotherapy, radiofrequency or microwave ablation (RFA),
stereotactic radiation therapy, radioactive microspheres, transarterial
(bland) embolization (TAE), and transarterial chemoembolization
(TACE). While nonresectional locoregional therapies are not curative,
these approaches do produce tumor destruction while preserving
nontumorous liver parenchyma and may serve as a bridge to more
definitive therapy, such as liver transplantation or as salvage treatment
for postresection recurrence.82-86
RFA uses radiowaves delivered via an electrode directly inserted
into a tumor to create a zone of thermal necrosis to destroy the tumor.
RFA can be performed percutaneously, laparoscopically, or through
an open incision and is most effective in tumors  3 cm in diameter.
Larger tumors generally require multiple overlapping ablations or the
use of multiple-array probes. Traditionally, RFA (and any ablative
technique) has been limited by the inability to accurately evaluate
Table 1. Staging and Prognostic Systems in HCC
Author/Reference
Staging System








American Joint Committee on Cancer/
International Union Against Cancer
Tumor-Node-Metastasis
I, II, III, IV Tumor size and number, vascular
invasion, extrahepatic disease,
fibrosis.
Llovet et al39 BCLC Barcelona Clinic Liver Cancer A, B, C, D Tumor size, patient clinical status,
Child-Pugh class, tumor-related




CPT Child-Pugh-Turcotte A, B, C Developed to predict post-hepatectomy
risk of liver failure; includes ascites,
encephalopathy, nutritional status,
bilirubin, albumin, INR.
No authors listed42 CLIP Cancer of the Liver Italian Program Serum -fetoprotein  400 or  400
ng/mL; solitary or multiple tumor
nodules or massive tumor  50% of
the area of liver, portal vein
thrombosis.
Leung et al43 CUPI Chinese University Prognostic Index Serum bilirubin, ascites, alkaline
phosphatase; presence of
symptoms, TNM, fibrosis.
Cammà et al44 GRETCH Group d’Etude de la Traitement du
Carcinome Hepatocellulaire
A, B, C Serum bilirubin, alkaline phosphatase,
-fetoprotein  35 or  35 g/L,
portal vein thrombosis, performance
status.
Makuuchi et al45 IHPBA International Hepato-Pancreato-Biliary
Association
Depends on macroscopic findings after
liver resection; tumor size  2-3 cm,
no invasion of hepatic vein, portal
vein, or bile ducts.
Nanashima et al,46
Ikai et al47
JIS Japan Integrated Staging 0, 1, 2, 3, 4, 5 Combines Child-Pugh class and LCSGJ
TNM system.
LCSGJ Liver Cancer Study Group of Japan TNM.
Hayashi et al,48
Yao et al49
MELD Model for End-Stage Liver Disease MELD score is calculated on the basis
of the patient’s age, serum
creatinine, serum bilirubin, and INR
levels.
Okuda et al50 Okuda 1, 2, 3 Includes ascites, serum albumin and
bilirubin, tumor  50% or  50%
cross-sectional area of liver; shown
to have lower predictive ability when
compared with some of the newer
staging systems.
UNOS United Network for Organ Sharing Prioritizes donor organ allocation in 11
U.S. geographic regions. UNOS
policy awards additional points to
MELD score for patients with HCC
with one tumor  5 cm or  three
tumors  8 cm total, no extrahepatic
spread, no gross vascular invasion.
Abbreviations: HCC, hepatocellular carcinoma; INR, international normalized ratio.
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treatment margins in all three dimensions. In a nonrandomized, com-
parative study of 148 patients with solitary, small ( 4 cm) HCC, the
rate of local (near the margin of ablation) recurrence was found to be
as high as 7.3% after RFA compared with 0% after surgery.87 However,
in a recent prospective randomized trial of 180 patients with a solitary
HCC tumor  5 cm, percutaneous RFA and surgical resection were
associated with similar overall survival (OS; 68% v 64%) and disease-
free survival (46% v 52%) rates at 4 years.88 It has been suggested that
RFA may be more effective in patients with cirrhosis because the
fibrotic liver can act as insulation and confine the heat to the tumor,
creating the so-called “oven effect.”89 Nevertheless, there is no consen-
sus regarding the efficacy of RFA as first-line treatment for HCC;
currently, this technique is generally accepted as the best treatment for
small HCC in a patient whose tumor cannot be resected safely as a
means of preventing tumor progression before liver transplantation,
or as salvage treatment for patients who have tumor recurrence after
surgical treatment.
TACE is a locoregional therapy option that delivers chemother-
apy and embolic materials via hepatic arterial infusion. It is based on
the fact that HCC tumors  2 cm preferentially receive their blood
supply from the hepatic arterial circulation. Chemotherapy agents
may be either infused into the liver before embolization or impreg-
nated in the gelatin sponges used for the embolization.90,91 Lipiodol
has also been used in conjunction with TACE because this agent will
remain selectively in the tumors for an extended period, allowing the
delivery of locally concentrated therapy. The objective of TACE is to
bring arterial flow to stasis to effect ischemia as well as direct cytotoxic
tumor damage.92-94 TAE can also be performed omitting the chemo-
therapeutic agent.
The advantage of TACE compared with the best supportive care
has been suggested in two small randomized controlled trials. The first
study from the University of Hong Kong randomly assigned 80 pa-
tients with advanced HCC to TACE with an emulsion of cisplatin in
lipiodol and gelatin-sponge particles versus conservative manage-
ment. Two-year survival rates were significantly higher for the TACE
arm compared with the control group (31% v 11%; P  .006).95 In the
second TACE trial performed in Western Europe, patients were ran-
domly assigned to receive bland TAE, or supportive care doxorubicin
combined with lipiodol and absorbable gelatin (Gelfoam; Pfizer, Hay-
ward, CA). The 2-year survival rates were significantly better for the
TACE group than for the symptomatic control group (63% v 27%;
P  .009).96 However, subsequent controlled trials have not demon-
strated a survival benefit of TACE.97,98
Morbidity rates have been reported to be as high as 23% after
TACE, especially among patients with HCC tumors  10 cm in
diameter.99,100 Postembolization syndrome, including fever, nausea,
and pain, is common. Other complications, such as fatal hepatic
necrosis and liver failure are rare. TACE is generally contraindicated in
patients with decompensated liver failure.
HCC tumors are clinically chemotherapy-resistant tumors, an
observation supported by low response rates across a wide variety of
cytotoxic chemotherapy agents101 and, until recently, a lack of level
1 evidence that systemic therapy improves median OS in HCC
patients. In a pivotal, international, placebo-controlled clinical trial
(Sorafenib Hepatocellular Carcinoma Assessment Randomized Pro-
tocol [SHARP]), sorafenib significantly improved OS (10.7 v 7.9
months; P  .001), in patients with advanced HCC and Child-Pugh
class A cirrhosis.102 Sorafenib is a multikinase inhibitor with activity
against Raf kinase and several other cellular receptors, including vas-
cular endothelial growth factor 2 (VEGF2), platelet-derived growth
factor, FLT3, and c-Kit. In HCC cell lines, sorafenib inhibits prolifer-
ation and induces apoptosis.57,103,104
The approval of sorafenib in 2007 for the treatment of HCC
patients in both the United States and the European Union represents
a true paradigm shift in the treatment of advanced HCC and is a
clinically meaningful therapeutic advancement in this challenging
malignancy. Interestingly, a subsequent prospective controlled trial of
sorafenib in Asian patients with the same design and eligibility criteria
as the SHARP trial showed an improvement in OS with a hazard ratio
similar to that of the SHARP trial. However, the Asian study showed
significantly lower absolute benefit (6.2 months median survival in the
study arm v 10.7 months in SHARP) and possibly overall lower toler-
ance of sorafenib.105 Understanding the reasons for such differential
effects is essential to inform the design of future trials in HCC and
underscores the importance of identifying stratification factors in
future clinical trials, such as hepatic function, ethnicity, disease etiol-
ogy, and tumor molecular profile.
There remains a great need for safe and effective systemic thera-
pies for HCC patients who progressed on or do not tolerate sorafenib
and for patients with more advanced hepatic dysfunction. Sorafenib
provides a platform on which to build future clinical trials in both the
adjuvant and advanced disease settings.
SUMMARY OF THE CTPM CONSENSUS
Management of Patients With Advanced HCC:
Evaluation, Staging, Stratification, Treatment,
and Assessment of Therapeutic Response
The CTPM recommendations focused on the greatest unmet
need in HCC: the large majority of HCC patients with advanced
disease who will need systematic therapy. Many of the challenges in
designing clinical trials to develop effective systemic therapies for
advanced HCC are closely linked to other topics addressed by the
CTPM, including optimal imaging to assess drug activity, correlative
translational science, and HCC staging to facilitate design and com-
parison of clinical trials. Several critical features are lacking in all
current HCC staging and prognostic systems, including molecular
characterization of tumors and data to validate stratification of pa-
tients on the basis of etiology, ethnicity, geographic region, and other
factors yet to be elucidated. Microarray technology has revolutionized
the understanding of the molecular basis of several solid tumors,106,107
and comprehensive studies should be performed in HCC to identify
molecular profiles to improve cancer staging, prediction of recur-
rence, prognosis, and treatment selection. Emerging data provide
insight into distinct genetic and molecular differences across the spec-
trum of HCC.108-112 However, no adequately powered molecular
characterization across the spectrum of HCC has been completed.
Future prognostic studies should be performed in selected patient
populations to determine whether specific prognostic indicators are
relevant across the range of HCC and underlying liver disease.
There has been an explosion of technical advancements in
radiographic imaging that has resulted in a lowered threshold for
tumor size detection, improved ability to distinguish lesion
Thomas et al
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pathology, and improved assessment of tumor and liver vascular
features. Current state-of-the-art imaging technology, including
[18F]fluorodeoxyglucose–positron emission tomography (FDG-
PET), diffusion MRI, microbubble-enhanced ultrasound, and
[15O]-PET, are options that offer a greatly enhanced ability to
detect and follow HCC lesions and, in some settings, to assess
biologic tumor changes.113-115 While development of novel imag-
ing and image interpretation techniques is closely linked to assess-
ment of systemic therapy, there are major limitations to widespread
adoption of these advances: complex imaging processing require-
ments, low rate of FDG-PET avidity of HCC, need for multi-
institution reproducibility, and lack of validation of biologic
imaging end points.116,117
Several novel biologic agents in addition to sorafenib are now
being tested in HCC patients (Table 2). Hepatocarcinogenesis is a
complex multistep process characterized by a broad spectrum of mo-
lecular abnormalities that offers numerous potential therapeutic tar-
gets. Several key molecular pathways in HCC that represent rational
targets for novel therapy are summarized in the following sections.
MAPK Pathway
The mitogen-activated protein kinase (MAPK) pathway is in-
volved in cellular proliferation, differentiation, apoptosis, and sur-
vival. The pathway involves a cascade of phosphorylation of four
major cellular kinases: ras, RAF, MAP, and extracellular signal-
regulated kinase Erk (ERK). These intermediates are found to be
elevated in both HCC cell lines and human specimens.123,124 Thera-
peutic agents that target the MAPK pathway include sorafenib (which
targets both raf and vascular endothelial growth factor receptor
[VEGFR]), sunitinib,118,119,125 and farnesyl transferase inhibitors (tar-
geting ras).126,127
PI3K/Akt/mTOR Pathway
The phosphoinositide-3 kinase/protein kinase B/mammalian
target of rapamycin (PI3K/Akt/mTOR) pathway is a kinase cascade
effecting cellular proliferation and apoptosis and is closely linked to
the cell cycle. PI3K is associated with cell surface growth factor recep-
tors and, on ligand binding, can trigger formation of phosphatidylino-
sitol (3,4,5) -trisphosphate (PIP3), which in turn activates Akt and
leads to a number of downstream cellular events, mTOR being one of
the targets. This pathway is known to be upregulated in a subset of
HCC patients.128,129 Molecular targeted therapy such as rapamycin, a
naturally occurring mTOR inhibitor, showed promising results in
HCC cell lines.130 However, no published results from clinical trials of
any agents that target mTOR in HCC patients are available.
Growth Factor Dysregulation
Both the epidermal growth factor receptor (EGFR) and VEGFR
growth factor families are upregulated in HCC.131 EGFR is frequently
expressed in human hepatoma cells, and EGF may be one of the
mitogens needed for the growth of hepatoma cells.132 Several agents
that inhibit EGF signaling are clinically available, including gefitinib,
cetuximab, erlotinib, and panitumumab.133 Erlotinib is an orally ac-
tive and selective inhibitor of the EGFR/human epidermal growth
factor receptor 1 (HER1) –related tyrosine kinase enzyme. EGFR/
Table 2. Current Randomized Systemic Therapy Trials in Advanced HCC






for First Line Treatment of Patients
Diagnosed With Hepatocellular
Carcinoma (SEARCH)
III 700 Sorafenib: multikinase inhibitor
of Raf, VEGFR2, PDGFR,
FLT3, MEK, and ERK




III 1,050 OS, 10 months in
single-agent
HCC phase II trial
Brivinib: dual inhibition of FGF1
and VEGFR2
Comparison of Brivanib and Best
Supportive Care to Placebo for
Treatment of Liver Cancer for
Those Subjects Who Have Failed
Sorafenib Treatment
III 340 Brivinib: dual inhibition of FGF1
and VEGFR2
Bevacizumab and Erlotinib or Sorafenib
as First-Line Therapy in Treating
Patients With Advanced Liver
Cancer
Thomas et al121 Randomized
phase II
120 OS, 15.65 months,










Sorafenib Tosylate With or Without
Doxorubicin Hydrochloride in
Treating Patients With Locally














Efficacy and Tolerability of ABT-869
Versus Sorafenib in Advanced
Hepatocellular Carcinoma (HCC)
Huynh et al122 III 900 OS, 9.7 months in
single-agent phase
II trial
ABT-869: RTK inhibitor of
VEGF, PDGF
Abbreviations: HCC, hepatocellular carcinoma; VEGFR2, vascular endothelial growth factor receptor 2; PDGFR, platelet-derived growth factor receptor; FLT3,
FMS-like tyrosine kinase 3; MEK, mitogen activated protein (MAP/ extracellular signal-related kinase (ERK) kinase; OS, overall survival; CSF1R, colony stimulating
factor 1 receptor; FGF1, fibroblast growth factor 1; TTP, time to progression; mAB, monoclonal antibody; RTK, receptor tyrosine kinase; EGFR1, endothelial growth
factor receptor 1.
Relative to OS and TTP of 10.7 and 5.5 months, respectively for sorafenib.102
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HER1 expression was detected in HCC specimens by immunohisto-
chemistry in 88% of the patients enrolled in a phase II study of
erlotinib.134 In two phase II studies of this agent, the response rates
were  10%, but the disease control rate was more than 50%, and
median survival times were 10.75 and 13 months.134,135
HCCs are generally hypervascular, and VEGF promotes HCC
development and metastasis.136-138 Various agents targeting the VEGF
circulating ligand or transmembrane receptor, including bevaci-
zumab, sorafenib, and brivanib, have been studied in patients with
HCC.105,139-143 Bevacizumab, a monoclonal antibody inhibitor of the
VEGF ligand, has been investigated in phase II studies alone or in
combination with other agents.142,143These studies showed a disease
control rate of more than 80% and a median progression-free survival
of more than 6 months. Sorafenib exerts an antiangiogenic effect by
targeting VEGFR2/VEGFR3.58,144,145 The establishment of sorafenib
as the current standard-of-care systemic therapy for advanced HCC
patients provides a platform on which to build rational and safe
combination therapies.
There are seven priorities recommended for future studies in
advanced HCC:
1. The existence of numerous competing phase II and phase III
trials may impair accrual to all trials because of limited pa-
tient availability. The NCI, in conjunction with the GISC
(with awareness of industry-sponsored studies) should pri-
oritize trials that have substantial scientific rationale for ad-
vancing new agents in HCC from phase I to II to III. Trials
that have emanated from the GISC are listed in Table 3.
Agents with new mechanisms of action should be given pri-
ority over those that address previously targeted molecu-
lar mechanisms.
2. The GISC for systemic therapy trials in HCC supports the
following clinical trial design parameters:
● Sorafenib is suggested as the control in first-line trials.
Trials comparing new agents versus sorafenib and new
agents in combination with sorafenib versus sorafenib
alone are a priority. In the absence of standard-of-care
second-line therapy, randomized second-line trials should
beplacebo-controlled.
● Randomized phase II trials using time to progression as a pri-
mary end point or co-primary end point are encouraged.
● Identification and validation of stratification factors for
randomized studies is a priority.
● Preclinical data supporting the study of specific agents in
second-line therapy should be developed.
● Organ dysfunction studies should be performed during
early clinical development of new agents for therapy
in HCC.
● Tissue biorepositories should be created to support correl-
ative studies, preferably a national or international tis-
sue bank.
3. Studies to identify circulating biomarkers to complement
analysis of HCC tissue should be conducted.
4. Novel imaging correlative end points should be defined for
HCC (consider evaluating percent tumor necrosis and viable
tumor volume) since RECIST is acknowledged as a subopti-
mal tool for evaluating efficacy of biologic agents in HCC
because of noncompliant cirrhotic liver. Centralized image
review and a dedicated site radiologist in clinical trials should
be encouraged, and correlative end points should be vali-
dated prospectively in clinical trials.
5. Novel imaging methods (PET, diffusion MRI, and perfusion
methods such as delayed contrast enhancement (DCE) -MRI
or DCE-CT should be prospectively studied. Controlled
comparison of DCE-MRI versus DCE-CT in HCC should be
conducted. Collaboration with the American College of Ra-
diology Imaging Network (ACRIN) is encouraged.
6. Tumor markers screening at-risk populations and assessing
treatment response should be developed and validated.
Table 3. CTPM Priority Clinical Trials in HCC
Trial Sponsor Status
Sorafenib Tosylate With or Without Doxorubicin
Hydrochloride in Treating Patients With Locally
Advanced or Metastatic Liver Cancer CALGB-80802 Actively recruiting
Trial of Beads Versus Doxorubicin Eluting Beads for Arterial
Embolization of Hepatocellular Carcinoma MSKCC Actively recruiting
A Study of IMC-A12 in Combination With Sorafenib
in Patients With Advanced Cancer of the Liver ImClone Systems
A Phase III Randomized, Double-Blind Trial of
Chemoembolization With or Without Sorafenib in
Unresectable Hepatocellular Carcinoma (HCC) in
Patients With and Without Vascular Invasion ECOG E-1208 Actively recruiting
Sorafenib as Adjuvant Treatment in the Prevention
of Recurrence of Hepatocellular Carcinoma (STORM) Industry Actively recruiting
Sorafenib Therapy Prior to Radiofrequency Ablation for
Intermediate Sized Hepatocellular Cancer Beth Israel Deaconess Medical Center
Phase 3 Study of ThermoDox With Radiofrequency
Ablation (RFA) in Treatment of Hepatocellular
Carcinoma (HCC) Industry Actively recruiting
Trial of Beads Versus Doxorubicin Eluting Beads for Arterial
Embolization of Hepatocellular Carcinoma MSKCC Actively recruiting
Abbreviations: CTPM, Clinical Trials Planning Meeting; HCC, hepatocellular carcinoma; CALGB, Cancer and Leukemia Group B; MSKCC, Memorial Sloan-Kettering
Cancer Center; ECOG, Eastern Cooperative Oncology Group.
Trial developed by the National Cancer Institute Gastrointestinal Study Group.
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7. Phase zero studies of imaging modalities, including multiple
institutional sites for validation, should be considered.
Regional Therapy
Regional therapy includes intrahepatic arterial delivery of a
variety of agents, including chemotherapy with or without embolic
material, drug-eluting beads (DEB), or yttrium-90 (90Y) –labeled mi-
crospheres, to induce tumor shrinkage by ischemia, direct cytotoxic
effect, or radiation cytotoxicity. There is significant variability in the
levels of evidence that exist for the various agents and techniques used
in intrahepatic therapy for HCC. Patients with solitary HCC tumors
 8 cm, no vascular invasion or extrahepatic spread, and compen-
sated liver function have been shown to derive benefit from conven-
tional TACE in two small, randomized, controlled trials.95,96
Technical advances, increasing practitioner expertise, and wide varia-
tion in individual interventional radiology practice patterns have
largely driven the growth of locoregional therapy for HCC. A substan-
tial body of empiric data has evolved, in most cases from single-
institution cohort studies, that generally supports the use of
intrahepatic regional therapy in a broad range of HCC patients, except
those with massive or bilobar tumors, main portal vein thrombus, and
advanced liver disease. Yet because of the lack of controlled, prospec-
tive clinical trials of regional therapy, there remains a clear need to
provide evidence supporting which HCC patient populations will
derive benefit.146 While the field is evolving rapidly, regional therapies
such as TACE, radio-labeled microspheres, and DEB are particularly
costly and not without adverse effects. There is a need for studies to
clarify the optimal use of these techniques in terms of patient safety,
efficacy, and cost-effectiveness. Further, there is increasing evidence
that intrahepatic therapies can stimulate cytokine production that
may, in fact, drive tumor progression;147,148 thus, evaluating the role of
concurrent targeted systemic therapies is essential.
There are several priorities for clinical evaluation of re-
gional therapy:
1. Conduct prospective phase II and III trials of combined
modalities, including TACE plus ablation and TACE plus
systemic therapy.
2. Evaluate the outcome of regional therapy versus systemic
therapy in patients with N1 or M1 disease.
3. Design clinical trials of regional therapy approaches to clearly
identify the patient population being studied. Significant
overlap exists between populations deemed suitable for re-
gional approaches and those with more advanced disease
because of the lack of prospective controlled trials of regional
therapy. The highly variable time to progression and OS of
this large patient group confound interpretation of phase II
trial results.
4. Conduct comparison trials of TACE, DEB, and Y90-labeled
microspheres to assess safety, efficacy, and cost-effectiveness
end points.
5. Define the role of TACE in liver transplantation by finding
answers to these questions: Does TACE response have an
impact on the outcome in OLT? What is the efficacy of TACE
as a bridge to OLT? Does pre-OLT TACE improve post-
transplantation survival? and What is the outcome of TACE
to downstage patients who were initially outside UNOS criteria?
6. Conduct prospective trials of regional therapy options. There
would be numerous challenges, including standardization of
technique, investigator bias/preference, competing trials,
high cost, variability in OLT wait time across UNOS regions,
and lack of consistent access to OLT programs and patients
for the cooperative groups.
7. The Eastern Cooperative Oncology Group (ECOG 1208; Ta-
ble 3) trial, A Phase III Randomized, Double-Blind Trial of
Chemoembolization With or Without Sorafenib in Unre-
sectable Hepatocellular Carcinoma (HCC) in Patients With
and Without Vascular Invasion, is actively recruiting patients
and is a priority study.
Local Therapy
Partial hepatic resection is an option for many HCC patients,
including those who are not candidates for liver transplantation and
those whose tumor is confined to one lobe of the liver and who have no
portal hypertension, no extrahepatic spread, or gross vascular inva-
sion. A variety of ablative techniques are also used to treat small ( 3-4
cm) HCC not located adjacent to vascular structures. Newer tech-
niques using external-beam radiotherapy may be able to successfully
treat somewhat larger tumors and those adjacent to the vasculature.
Few randomized trials have been performed that evaluate relative
benefits and morbidity of resection compared with ablation.
There are several priorities for clinical evaluation of local therapy.
1. Evaluate the outcome of adjuvant systemic therapy following
resection or ablation. The Sorafenib as Adjuvant Treatment
in the Prevention of Recurrence of Hepatocellular Carci-
noma (STORM) trial (Table 3) is an industry-sponsored trial
that opened to accrual in August 2008. The target enrollment
for this randomized, placebo-controlled, international study
is 1,100 patients and will include patients who have received
surgical resection or local ablation. The primary end point of
the study is recurrence-free survival in patients who receive
sorafenib 400 mg twice per day for up to 4 years. Secondary
end points include OS, time to recurrence, patient-reported
outcomes, plasma biomarkers, safety, and tolerability.
2. Conduct a phase II trial of adjuvant chemotherapy following
intrahepatic therapy, DEB, or Y90-labeled microspheres.
● Feasibility: low due to lack of adequate data for historical
controls, small numbers of patients, and uncertain end
points and goals for go or no-go decisions for larger random-
ized trials.
3. Compare modalities, such as hepatic resection versus ablation.
● End points: recurrence-free survival and equivalence ver-
sus superiority, morbidity, and mortality.
● Feasibility: multiple challenges include study design and
institutional and individual clinician bias that would im-
pair accrual.
Liver Transplantation
OLT was performed in 6,493 patients in the United States in 2007
for all indications: approximately 20% (1,300) of those patients had
HCC. Although the published survival rates are  75% for patients
who received transplantation within UNOS criteria, a measurable
number of HCC patients who receive liver transplantation will de-
velop recurrent tumor or recurrent underlying liver disease and will
die of their disease. Since the principal factor affecting the availability
of OLT as a treatment option is limited by the supply of donor organs,
OLT is expected to remain an option for only a small minority of HCC
HCC Clinical Trials Planning Meeting
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patients. However, there are several aspects of OLT for HCC that can
be further optimized.
These clinical questions illustrate the key knowledge gaps in liver
transplantation for HCC identified by the CTPM: What is the role of
using neoadjuvant or bridge-to-transplantation therapy? What are the
role and the appropriateness of using neoadjuvant therapies to down-
stage patients to within UNOS criteria? and What is the efficacy of
adjuvant therapy in decreasing cancer recurrence and improving
long-term survival?
There are several priorities for clinical evaluation of liver trans-
plantation that involve downstaging therapy and adjuvant therapy.
1. Downstaging therapy:
● Clinicalquestions:CanpatientsoutsideUNOScriteriabenefit
from transplantation, and if so, which patients? Are there
biomarkers that can correlate neoadjuvant therapy (eg,
TACE) with outcome (radiographic response or survival)?
● Trial concept: phase II, single-arm (more than UNOS cri-
teria and less than or equal to UCSF criteria), treated with
TACE; surveillance with functional imaging every 3
months and TACE repeated every 3 months as needed.
Patient would remain listed for transplantation.
● Correlative science: functional imaging, biomarkers, and
gene expression in liver explants.
● End points: rate of dropout from transplantation list, survival
(intent-to-treat analysis), and recurrence-free survival.
● Feasibility: considered not feasible for cooperative groups
because of the relatively small number of patients and the
lack of specific UNOS participation in the GI Intergroup.
2. Adjuvant therapy:
● Clinical questions: Can adjuvant therapy improve post-
OLT outcome in patients at high risk for recurrence (de-
fined as outside UNOS criteria, high preoperative AFP,
and vascular/lymphatic invasion in explants)?
● Trial concept: randomized phase II and phase III trials of
sorafenib (or other tyrosine kinase inhibitor), post-
transplantation genetic profiling of tumor (to develop
molecular markers), random assignment to sorafenib ver-
sus placebo, and surveillance every 3 months with imaging
and serum AFP.
● End points: graft survival, toxicity and safety, disease-free
survival, OS, and biologic markers to correlate with sur-
vival and recurrence.
● Feasibility: low because participation by multiple transplanta-
tion centers with medical oncology support would be required.
In conclusion, hepatocellular carcinoma is one of the most
common malignancies in the world and is a complex tumor that is
steadily rising in incidence in the United States and other western
countries. The majority of patients diagnosed with HCC have
advanced disease, and these patients represent the highest priority
for development of effective therapies. Advanced HCC remains a
significant unmet medical need for which available research re-
sources should be prioritized. Current and future clinical trials
could identify additional effective systemic agents, combination
systemic therapies, and combined modality options. As advance-
ments in developing personalized therapy continue to evolve for
other tumors, it will be essential for the HCC community to de-
velop tissue, serum, and other validated biomarkers that can help
identify those patients who will benefit most from emerging treat-
ment options.
Although the CTPM did not specifically address prevention and
early detection of HCC, it is ideal to prevent, rather than treat, an
advanced malignancy. The risk factors for developing HCC are well
known. Clearly HCC is a preventable cancer and is an ideal focus for
cancer prevention and control strategies.
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